United Imaging Spotlights Molecular Imaging Showstoppers at SNMMI 2026
Press Release

United Imaging Spotlights Molecular Imaging Showstoppers at SNMMI 2026

LOS ANGELES, May 31, 2026 /PRNewswire/ — United Imaging, a global innovator in AI-powered advanced medical imaging technologies and intelligent healthcare solutions, is presenting its latest molecular imaging advancements at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting. Aligning with the official conference theme, "Science is the star," the company is […]

Read More
BLUETTI Launches EOFY Sale on Power Solutions with Up to 44% OFF
Press Release

BLUETTI Launches EOFY Sale on Power Solutions with Up to 44% OFF

SYDNEY, June 1, 2026 /PRNewswire/ — Clean energy leader BLUETTI is unleashing massive EOFY deals during June 1–30, up to 44% off its diverse portable power stations and home backup systems. The world’s smallest 3kWh power station Elite 300, the best entry-level Elite 100 V2, and the versatile Apex 300 headline the shopping spree of […]

Read More
Relief as Firmable locates 15,000 accounting decision-makers reported missing at leading global B2B data provider
Press Release

Relief as Firmable locates 15,000 accounting decision-makers reported missing at leading global B2B data provider

Sydney-based sales team initiates platform support ticket after discovering significantly more contacts than expected. Investigation concludes that data is correct. MELBOURNE, Australia and SINGAPORE, May 31, 2026 /PRNewswire/ — Firmable, Asia-Pacific’s leading AI-native sales platform, has confirmed the safe recovery of approximately 15,000 Australian accounting firm decision-makers previously unaccounted for in the data holdings of […]

Read More
HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
Press Release

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session

CHICAGO, May 31, 2026 /PRNewswire/ — Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the Company’s first-in-class PD-1/VEGF bispecific antibody, has achieved a statistically significant and clinically meaningful improvement in overall survival (OS) as a first-line treatment for patients with advanced squamous non-small cell lung cancer (sq-NSCLC) in the Phase III HARMONi-6 […]

Read More
Golden Goblet Competition Lineup Announced: Spotlight on the 2026 Contenders
Press Release

Golden Goblet Competition Lineup Announced: Spotlight on the 2026 Contenders

SHANGHAI, May 31, 2026 /PRNewswire/ — The 28th Shanghai International Film Festival (SIFF) has officially unveiled the competition selections for the 2026 Golden Goblet Awards. https://static.prnasia.com/pro/fec/jwplayer-7.12.1/jwplayer.js jwplayer.key=”3Fznr2BGJZtpwZmA+81lm048ks6+0NjLXyDdsO2YkfE=”   jwplayer(‘myplayer1’).setup({file: ‘https://mma.prnasia.com/media2/2991369/Video.mp4’, image: ‘https://mma.prnasia.com/media2/2991369/Video.mp4?p=medium’, autostart:’false’, stretching : ‘uniform’, width: ‘512’, height: ‘288’}); Held from June 12 to 21, the Festival received approximately 4,100 submissions from 125 countries […]

Read More
Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
Press Release

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026

Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third-generation EGFR TKI In treatment-naïve patients with advanced NSCLC without driver mutations, Golidocitinib, a JAK-only inhibitor, in combination with anti-PD-1 antibody enhanced anti-tumor response.  SHANGHAI, May 31, 2026 /PRNewswire/ — Dizal (SSE:688192), a […]

Read More
Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
Press Release

Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet

CHENGDU, China, May 31, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the results of the Phase III clinical study OptiTROP-Lung05, evaluating the company’s trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870)(佳泰莱®) in combination with pembrolizumab (KEYTRUDA®[1], MSD’s anti-programmed cell death protein […]

Read More

Sign In

Register

Reset Password

Please enter your username or email address, you will receive a link to create a new password via email.